Home/Filings/4/0001209191-22-033517
4//SEC Filing

Jiao Jin-an 4

Accession 0001209191-22-033517

CIK 0001828673other

Filed

Jun 1, 8:00 PM ET

Accepted

Jun 2, 4:16 PM ET

Size

11.2 KB

Accession

0001209191-22-033517

Insider Transaction Report

Form 4
Period: 2022-05-31
Jiao Jin-an
VP of Development
Transactions
  • Exercise/Conversion

    Common Stock

    2022-05-31$0.21/sh+1,714$36045,141 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-05-3112,85618,001 total
    Exercise: $0.14Exp: 2029-05-29Common Stock (12,856 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-05-311,7146,857 total
    Exercise: $0.21Exp: 2030-12-22Common Stock (1,714 underlying)
  • Exercise/Conversion

    Common Stock

    2022-05-31$0.14/sh+12,856$1,80043,427 total
Footnotes (2)
  • [F1]These option shares were part of a stock option grant covering 51,428 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant will vest on May 30, 2022; and 35% of the total shares subject to the stock option grant will vest on May 30, 2023.
  • [F2]20% of the total shares subject to the stock option grant will vest on December 22, 2021; 20% of the total shares subject to the stock option grant will vest on December 22, 2022; 25% of the total shares subject to the stock option grant will vest on December 22, 2023; and 35% of the total shares subject to the stock option grant will vest on December 22, 2024.

Issuer

HCW Biologics Inc.

CIK 0001828673

Entity typeother

Related Parties

1
  • filerCIK 0001866271

Filing Metadata

Form type
4
Filed
Jun 1, 8:00 PM ET
Accepted
Jun 2, 4:16 PM ET
Size
11.2 KB